Egypt
hyperlipidemia drugs market is expected to grow at an impressive rate during
the forecast period, 2024-2028. The major factors include
increase in the prevalence of the condition, rising awareness of the health
risks associated with hyperlipidemia, government initiatives to improve
healthcare infrastructure, increase in disposable income, and the introduction
of innovative drugs.
Hyperlipidemia,
a medical condition characterized by elevated levels of cholesterol and
triglycerides in the blood, is a significant health concern in Egypt. The
condition affects millions of Egyptians and is a major risk factor for cardiovascular
diseases.
The primary factor fueling the growth of the hyperlipidemia
drugs market in Egypt is the increase in the prevalence of the hyperlipidemia.
A sedentary lifestyle, unhealthy diet, and genetic factors are among the major
contributors to the rising incidence of hyperlipidemia in Egypt.
The awareness of the health risks associated with
hyperlipidemia has been steadily increasing among the population in Egypt. This
has led to an increased demand for hyperlipidemia drugs, as more people seek
medical intervention to manage their condition. The growing awareness of the
health risks associated with hyperlipidemia has also led to an increase in the
number of screening programs and campaigns aimed at early detection of the
condition.
The Egyptian government has been investing heavily in the
healthcare sector in recent years, with a particular focus on improving the
infrastructure and facilities available for medical care. This has led to an
increase in the availability of hyperlipidemia drugs, as well as improved access
to medical care for those who need it.
The field of medicine has seen significant technological
advancements in recent years, and the hyperlipidemia drugs market in Egypt has
not been left behind. The development of new technologies has led to the
creation of innovative drugs and treatments, which have improved the management
and treatment of hyperlipidemia. The introduction of innovative hyperlipidemia
drugs in the market has also contributed to the growth of the market. New drugs
that are more effective in controlling cholesterol levels and have fewer side
effects have been introduced in recent years, leading to an increased demand
for these drugs. Gene therapy, nanotechnology, artificial intelligence,
wearable technology, and telemedicine are just some of the advancements that
have improved the management and treatment of hyperlipidemia.
The increased demand for personalized medicine, growing
interest in natural and alternative therapies, increased focus on preventative
care, growing aging population, and technological advancements are expected to
influence the growth of the market.
There is a growing focus on prevention of hyperlipidemia and
its associated health risks in Egypt. This is leading to an increased emphasis
on lifestyle modifications, including changes to diet and exercise, as well as
the use of preventive medication such as statins. This increased focus on
prevention is expected to support the growth of the hyperlipidemia drugs market
in the forecast period.
Pharmaceutical companies are investing in advancements in
drug delivery technologies, which is expected to drive the growth of the Egypt
hyperlipidemia drugs market. For example, newer drug delivery systems can
improve the bioavailability of the drug and reduce side effects, making them
more effective and tolerable for patients.
The increasing investment in healthcare infrastructure in
Egypt is expected to support the growth of the hyperlipidemia drugs market.
This includes investments in healthcare facilities, medical technology, and healthcare
personnel. As a result, patients are likely to have better access to medical
treatment, including hyperlipidemia drugs, which will drive the growth of the
market.
The increasing use of digital health technology, including
telemedicine and mobile health applications, is also supporting the growth of
the Egypt hyperlipidemia drugs market. These technologies are making it easier
for patients to access medical care and manage their health conditions,
including hyperlipidemia. For example, patients can use mobile health
applications to track their lipid levels and receive personalized advice on
diet and lifestyle modifications, which can help reduce their risk of
cardiovascular events.
To meet the growing demand for hyperlipidemia drugs,
pharmaceutical companies are investing in research and development to develop
new and more effective treatments. This is expected to result in the launch of
new hyperlipidemia drugs in the coming years, further driving market growth.
However, there are several challenges that are hampering the
growth of the market in the forecast period. These challenges include limited
access to healthcare services, high cost of drugs, lack of patient awareness,
limited availability of generic drugs, and regulatory challenges. The high cost
of hyperlipidemia drugs is a significant challenge for the growth of the market
in Egypt. Many patients in the country cannot afford the high cost of these
drugs, which can limit their access to treatment. This is especially true for
patients who do not have health insurance coverage or who have limited
financial resources.
The limited availability of generic hyperlipidemia drugs is
also a challenge for the growth of the market in Egypt. Generic drugs are often
more affordable than branded drugs and can increase access to treatment for
patients. However, there are few generic hyperlipidemia drugs available in the
market, which can limit their availability and affordability for patients.
Download Free Sample Report
Rising Awareness Regarding the Risks of Cardiovascular Disease
(CVD) Brought on by Prolonged Hypercholesterolemia
Rising awareness regarding the risks of cardiovascular
disease (CVD) brought on by prolonged hypercholesterolemia is expected to have
a significant impact on the growth of the Egypt hyperlipidemia drugs market in
the coming years. The rising prevalence of CVD in Egypt has led to a growing
awareness of the importance of controlling hyperlipidemia to prevent the
development of CVD. This increased awareness is expected to drive the demand
for hyperlipidemia drugs in the coming years.
The main driver of this increased awareness is the growing
availability of information on the risks of hyperlipidemia and CVD through
various channels, including media campaigns, patient education programs, and healthcare
provider training. This increased awareness has led to a greater understanding
of the importance of controlling hyperlipidemia to reduce the risk of CVD and
has resulted in more patients seeking medical treatment for the condition.
Moreover, healthcare providers are increasingly focusing on
prevention and early detection of hyperlipidemia and its associated health
risks, including CVD. This has led to more frequent lipid level screening for
patients, and early intervention to prevent the development of CVD. In
addition, the adoption of guidelines for the management of hyperlipidemia by
healthcare providers is also supporting the growth of the hyperlipidemia drugs
market.
Growing Prevalence of Hyperlipidemia
The growing prevalence of hyperlipidemia is expected to have
a significant impact on the growth of the Egypt hyperlipidemia drugs market in
the coming years. Hyperlipidemia is a medical condition characterized by high
levels of lipids (fats) in the blood, including cholesterol and triglycerides,
and is a major risk factor for cardiovascular disease (CVD) such as heart
attack and strokes.
Egypt is facing a significant burden of hyperlipidemia, with
a high prevalence of the condition among its population. The increasing
prevalence of hyperlipidemia in Egypt is attributed to several factors,
including changing dietary patterns, sedentary lifestyles, and increasing rates
of obesity and diabetes.
As the prevalence of hyperlipidemia continues to rise in
Egypt, the demand for hyperlipidemia drugs is expected to increase as well.
This is because hyperlipidemia is a chronic condition that requires ongoing
management, and patients may require long-term treatment with hyperlipidemia
drugs to control their lipid levels and reduce their risk of developing CVD.
Furthermore, as the population ages and life expectancy
increases, the incidence of hyperlipidemia is also expected to increase,
further driving demand for hyperlipidemia drugs. In addition, the increasing
availability and affordability of hyperlipidemia drugs in Egypt is also
expected to support market growth.
Market Segmentation
The
Egypt hyperlipidemia drugs market can be segmented by drug
class, distribution
channel, and region. By drug class, the market can
be segmented into statins, bile acid sequestrants, cholesterol absorption
inhibitors, PCSK9 inhibitors, combination, and others. Based on distribution
channel, the market is further segmented into hospital pharmacy, retail
pharmacy, and online pharmacy.
Market Players
Amoun Pharmaceutical Company,
Pharco Corporation, EIPICO (Egyptian International Pharmaceutical Industries
Company), Rameda Pharmaceuticals, Minapharm Pharmaceuticals, Delta Pharma,
Memphis For Pharmaceutical & Chemical Industries, and Biopharm Group Egypt are
among others some
of the leading companies operating in the market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2022
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, Volume Units, and CAGR for 2018-2022
and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, volume forecast company share, competitive landscape, growth
factors, and trends
|
|
Segments
Covered
|
Drug Class
Distribution
Channel
|
|
Regional
Scope
|
Cairo, Qalyubia, Alexandria, Port Said, Giza, Suez
|
|
Key
Companies Profiled
|
Amoun Pharmaceutical Company, Pharco Corporation, EIPICO
(Egyptian International Pharmaceutical Industries Company), Rameda
Pharmaceuticals, Minapharm Pharmaceuticals, Delta Pharma, Memphis For
Pharmaceutical & Chemical Industries, and Biopharm Group
|
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, Egypt hyperlipidemia
drugs market has been segmented into following categories, in addition to the
industry trends which have also been detailed below:
·
Egypt Hyperlipidemia Drugs Market, By Drug Class
o
Statins
o
Bile
Acid Sequestrants
o
Cholesterol
Absorption Inhibitors
o
PCSK9
Inhibitors
o
Combination
o
Others
·
Egypt
Hyperlipidemia Drugs Market, By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o
Online
Pharmacy
·
Egypt
Hyperlipidemia Drugs Market, By Region
o
Cairo
o
Qalyubia
o
Alexandria
o
Port
Said
o
Giza
o
Suez
o Rest of Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in Egypt hyperlipidemia drugs market has been provided.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market
players (up to five).